{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T04:02:58Z","timestamp":1742443378988,"version":"3.40.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,18]]},"DOI":"10.7759\/cureus.80795","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T04:03:36Z","timestamp":1742357016000},"source":"Crossref","is-referenced-by-count":0,"title":["Drug-Induced Liver Injury Secondary to Endocrine Therapy With Aromatase Inhibitors: A Case Report"],"prefix":"10.7759","author":[{"given":"Nicholas J","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sariah","family":"Watchalotone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21863","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto AN","year":"2024","unstructured":"Giaquinto AN, Sung H, Newman LA, et al.. Breast cancer statistics 2024. CA Cancer J Clin. 2024, 74:477-95. 10.3322\/caac.21863","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107607","article-title":"Aromatase inhibitors for the treatment of breast cancer: an overview (2019-2023)","volume":"151","author":"Bhatia N","year":"2024","unstructured":"Bhatia N, Thareja S. Aromatase inhibitors for the treatment of breast cancer: an overview (2019-2023). Bioorg Chem. 2024, 151:107607. 10.1016\/j.bioorg.2024.107607","journal-title":"Bioorg Chem"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq337","article-title":"The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum","volume":"22","author":"L\u00f8nning PE","year":"2011","unstructured":"L\u00f8nning PE. The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Ann Oncol. 2011, 22:503-14. 10.1093\/annonc\/mdq337","journal-title":"Ann Oncol"},{"key":"ref4","unstructured":"Label. ARIMIDEX- anastrozole tablet. (2012). Accessed: January 27, 2025: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=4fee8d4c-bb21-4773-b622-87f9a4ff333a."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18051018","article-title":"Drug-induced liver injury: cascade of events leading to cell death, apoptosis or necrosis","volume":"18","author":"Iorga A","year":"2017","unstructured":"Iorga A, Dara L, Kaplowitz N. Drug-induced liver injury: cascade of events leading to cell death, apoptosis or necrosis. Int J Mol Sci. 2017, 18:10.3390\/ijms18051018","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22062954","article-title":"Idiosyncratic drug-induced liver injury: mechanistic and clinical challenges","volume":"22","author":"Jee A","year":"2021","unstructured":"Jee A, Sernoskie SC, Uetrecht J. Idiosyncratic drug-induced liver injury: mechanistic and clinical challenges. Int J Mol Sci. 2021, 22:10.3390\/ijms22062954","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.04.033","article-title":"Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): an expert opinion meeting report","volume":"79","author":"Andrade RJ","year":"2023","unstructured":"Andrade RJ, Aithal GP, de Boer YS, et al.. Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): an expert opinion meeting report. J Hepatol. 2023, 79:853-66. 10.1016\/j.jhep.2023.04.033","journal-title":"J Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.11805","article-title":"Anastrozole-induced autoimmune hepatitis: a rare complication of breast cancer therapy","volume":"37","author":"Klapko O","year":"2017","unstructured":"Klapko O, Ghoulam E, Jakate S, Eswaran S, Usha L. Anastrozole-induced autoimmune hepatitis: a rare complication of breast cancer therapy. Anticancer Res. 2017, 37:4173-6. 10.21873\/anticanres.11805","journal-title":"Anticancer Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-008-0071-y","article-title":"Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer","volume":"15","author":"Iwase H","year":"2008","unstructured":"Iwase H. Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer. Breast Cancer. 2008, 15:278-90. 10.1007\/s12282-008-0071-y","journal-title":"Breast Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2009.12.010","article-title":"Adjuvant aromatase inhibitor therapy: outcomes and safety","volume":"36","author":"Janni W","year":"2010","unstructured":"Janni W, Hepp P. Adjuvant aromatase inhibitor therapy: outcomes and safety. Cancer Treat Rev. 2010, 36:249-61. 10.1016\/j.ctrv.2009.12.010","journal-title":"Cancer Treat Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.0946","article-title":"Advances in adjuvant endocrine therapy for postmenopausal women","volume":"26","author":"Lin NU","year":"2008","unstructured":"Lin NU, Winer EP. Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol. 2008, 26:798-805. 10.1200\/JCO.2007.15.0946","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-11-32","article-title":"Anastrozole-related acute hepatitis with autoimmune features: a case report","volume":"11","author":"Inno A","year":"2011","unstructured":"Inno A, Basso M, Vecchio FM, et al.. Anastrozole-related acute hepatitis with autoimmune features: a case report. BMC Gastroenterol. 2011, 11:32. 10.1186\/1471-230X-11-32","journal-title":"BMC Gastroenterol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.2028","article-title":"Drug-induced liver injury as assessed by the updated Roussel Uclaf Causality Assessment Method following mild COVID-19 in a patient under anastrozole therapy-a case report","volume":"7","author":"Lischka W","year":"2024","unstructured":"Lischka W, Kriegsh\u00e4user G. Drug-induced liver injury as assessed by the updated Roussel Uclaf Causality Assessment Method following mild COVID-19 in a patient under anastrozole therapy-a case report. Cancer Rep (Hoboken). 2024, 7:e2028. 10.1002\/cnr2.2028","journal-title":"Cancer Rep (Hoboken)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-014-0512-4","article-title":"A case of anastrazole-related drug-induced autoimmune hepatitis","volume":"7","author":"Islam MS","year":"2014","unstructured":"Islam MS, Wright G, Tanner P, Lucas R. A case of anastrazole-related drug-induced autoimmune hepatitis. Clin J Gastroenterol. 2014, 7:414-7. 10.1007\/s12328-014-0512-4","journal-title":"Clin J Gastroenterol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60017-8","article-title":"Severe acute hepatitis in a patient treated with anastrozole","volume":"369","author":"de la Cruz L","year":"2007","unstructured":"de la Cruz L, Romero-Vazquez J, Jim\u00e9nez-S\u00e1enz M, Padron JR, Herrerias-Gutierrez JM. Severe acute hepatitis in a patient treated with anastrozole. Lancet. 2007, 369:23-4. 10.1016\/S0140-6736(07)60017-8","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/01.meg.0000243868.64078.af","article-title":"Anastrozole-induced hepatotoxicity","volume":"18","author":"Zapata E","year":"2006","unstructured":"Zapata E, Zubiaurre L, Bujanda L, Pi\u00e9rola A. Anastrozole-induced hepatotoxicity. Eur J Gastroenterol Hepatol. 2006, 18:1233-4. 10.1097\/01.meg.0000243868.64078.af","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases","volume":"72","author":"Mack CL","year":"2020","unstructured":"Mack CL, Adams D, Assis DN, et al.. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology. 2020, 72:671-722. 10.1002\/hep.31065","journal-title":"Hepatology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17010014","article-title":"RUCAM in drug and herb induced liver injury: the update","volume":"17","author":"Danan G","year":"2015","unstructured":"Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2015, 17:10.3390\/ijms17010014","journal-title":"Int J Mol Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/341352-drug-induced-liver-injury-secondary-to-endocrine-therapy-with-aromatase-inhibitors-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T04:03:38Z","timestamp":1742357018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/341352-drug-induced-liver-injury-secondary-to-endocrine-therapy-with-aromatase-inhibitors-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.80795","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,18]]}}}